NEXGEL (NXGLW) Competitors

NEXGEL logo
$0.0099 +0.00 (+22.28%)
As of 01:16 PM Eastern
This is a fair market value price provided by Massive. Learn more.

NXGLW vs. LUCYW, WOK, MDLN, ALC, and WST

Should you buy NEXGEL stock or one of its competitors? NEXGEL's main competitors and comparable companies include Innovative Eyewear (LUCYW), WORK Medical Technology Group (WOK), Medline (MDLN), Alcon (ALC), and West Pharmaceutical Services (WST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does NEXGEL compare to Innovative Eyewear?

NEXGEL (NASDAQ:NXGLW) and Innovative Eyewear (NASDAQ:LUCYW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

In the previous week, NEXGEL and NEXGEL both had 1 articles in the media. Innovative Eyewear's average media sentiment score of 1.43 beat NEXGEL's score of 0.71 indicating that Innovative Eyewear is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NEXGEL
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Innovative Eyewear
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Innovative Eyewear N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Innovative Eyewear$3.41MN/AN/AN/AN/A

Summary

NEXGEL and Innovative Eyewear tied by winning 1 of the 2 factors compared between the two stocks.

How does NEXGEL compare to WORK Medical Technology Group?

NEXGEL (NASDAQ:NXGLW) and WORK Medical Technology Group (NASDAQ:WOK) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
WORK Medical Technology Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NEXGEL has higher revenue and earnings than WORK Medical Technology Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
WORK Medical Technology Group$9.81MN/A-$1.07MN/AN/A

In the previous week, NEXGEL had 1 more articles in the media than WORK Medical Technology Group. MarketBeat recorded 1 mentions for NEXGEL and 0 mentions for WORK Medical Technology Group. WORK Medical Technology Group's average media sentiment score of 1.79 beat NEXGEL's score of 0.71 indicating that WORK Medical Technology Group is being referred to more favorably in the news media.

Company Overall Sentiment
NEXGEL Positive
WORK Medical Technology Group Very Positive

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
WORK Medical Technology Group N/A N/A N/A

Summary

NEXGEL and WORK Medical Technology Group tied by winning 2 of the 4 factors compared between the two stocks.

How does NEXGEL compare to Medline?

Medline (NASDAQ:MDLN) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends, media sentiment and profitability.

Medline has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.81$1.16B$0.4489.09
NEXGEL$12.07MN/AN/AN/AN/A

Medline has a net margin of 1.84% compared to NEXGEL's net margin of 0.00%. Medline's return on equity of 8.21% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
Medline1.84% 8.21% 4.03%
NEXGEL N/A N/A N/A

Medline currently has a consensus target price of $46.08, suggesting a potential upside of 17.55%. Given Medline's stronger consensus rating and higher probable upside, research analysts plainly believe Medline is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
2 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
0 Strong Buy rating(s)
2.72
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Medline had 20 more articles in the media than NEXGEL. MarketBeat recorded 21 mentions for Medline and 1 mentions for NEXGEL. Medline's average media sentiment score of 0.89 beat NEXGEL's score of 0.71 indicating that Medline is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
6 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NEXGEL
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Medline beats NEXGEL on 9 of the 9 factors compared between the two stocks.

How does NEXGEL compare to Alcon?

NEXGEL (NASDAQ:NXGLW) and Alcon (NYSE:ALC) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Alcon has a consensus target price of $82.16, suggesting a potential upside of 9.33%. Given Alcon's stronger consensus rating and higher possible upside, analysts plainly believe Alcon is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63

53.9% of Alcon shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Alcon had 12 more articles in the media than NEXGEL. MarketBeat recorded 13 mentions for Alcon and 1 mentions for NEXGEL. NEXGEL's average media sentiment score of 0.71 beat Alcon's score of 0.25 indicating that NEXGEL is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NEXGEL
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alcon
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alcon has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NEXGEL$12.07MN/AN/AN/AN/A
Alcon$10.40B3.57$980M$1.3754.86

Alcon has a net margin of 6.06% compared to NEXGEL's net margin of 0.00%. Alcon's return on equity of 7.54% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
NEXGELN/A N/A N/A
Alcon 6.06%7.54%5.25%

Summary

Alcon beats NEXGEL on 10 of the 11 factors compared between the two stocks.

How does NEXGEL compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and NEXGEL (NASDAQ:NXGLW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

93.9% of West Pharmaceutical Services shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

West Pharmaceutical Services currently has a consensus price target of $424.67, indicating a potential upside of 4.56%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, research analysts plainly believe West Pharmaceutical Services is more favorable than NEXGEL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93
NEXGEL
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, West Pharmaceutical Services had 5 more articles in the media than NEXGEL. MarketBeat recorded 6 mentions for West Pharmaceutical Services and 1 mentions for NEXGEL. West Pharmaceutical Services' average media sentiment score of 1.01 beat NEXGEL's score of 0.71 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NEXGEL
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

West Pharmaceutical Services has higher revenue and earnings than NEXGEL.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B9.20$493.70M$8.9145.58
NEXGEL$12.07MN/AN/AN/AN/A

West Pharmaceutical Services has a net margin of 18.81% compared to NEXGEL's net margin of 0.00%. West Pharmaceutical Services' return on equity of 21.78% beat NEXGEL's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services18.81% 21.78% 15.99%
NEXGEL N/A N/A N/A

Summary

West Pharmaceutical Services beats NEXGEL on 11 of the 11 factors compared between the two stocks.

Get NEXGEL News Delivered to You Automatically

Sign up to receive the latest news and ratings for NXGLW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NXGLW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NXGLW vs. The Competition

MetricNEXGELHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$5.96B$7.66B$11.73B
Dividend YieldN/A1.68%2.47%4.46%
P/E RatioN/A38.9634.0030.04
Price / SalesN/A5.458.445.70
Price / CashN/A23.6221.0121.90
Price / BookN/A4.244.483.75
Net IncomeN/A$143.92M$3.51B$394.12M
7 Day PerformanceN/A-5.22%-5.93%-5.63%
1 Month PerformanceN/A-3.34%-4.31%-6.93%
1 Year PerformanceN/A0.43%-1.15%-7.12%

NEXGEL Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NXGLW
NEXGEL
N/A$0.01
+22.3%
N/A-96.8%$0.00$12.07MN/A19
LUCYW
Innovative Eyewear
N/A$0.04
-4.7%
N/A-58.5%$0.00$3.41MN/A13
WOK
WORK Medical Technology Group
N/A$1.25
-8.8%
N/A-100.0%$0.00$10.72MN/A238
MDLN
Medline
3.2699 of 5 stars
$39.98
-5.2%
$46.08
+15.2%
N/A$52.56B$28.43B90.8745,000
ALC
Alcon
2.6145 of 5 stars
$71.74
-1.0%
$82.16
+14.5%
-3.1%$35.48B$10.98B52.3625,942

Related Companies and Tools


This page (NASDAQ:NXGLW) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners